REBUILDING HEARTS WITH CRISPR-CAS9

Cardiovascular disease (CVD) remains the leading global cause of mortality, responsible for nearly 17.9 million deaths annually, with a disproportionate impact on low- and middle-income countries. CRISPR-Cas9, presents unprecedented opportunities to transform cardiovascular care from reactive treatment to proactive prevention. This paper explores the applications of CRISPR-Cas9 in repairing genetic mutations linked to hypertrophic cardiomyopathy (HCM) and other heritable cardiac conditions. Studies in somatic cell editing, lipid nanoparticle delivery systems, and polygenic risk scoring, the paper highlights both the promise and limitations of gene-editingstrategies.